SCHEMBL6961970

SCHEMBL6961970

CC(C)CCN1CCC[C@H](O)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
HTR1A P08908 1/20 0.44
KDM4E B2RXH2 4/20 0.44
HRH2 P25021 1/20 0.39
HRH1 P35367 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
POLB P06746 2/20 0.39
TSHR P16473 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTT P42858 2/20 0.38
GAA P10253 1/20 0.38
XBP1 P17861 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ROCK2 O75116 2/20 0.37
ROCK1 Q13464 2/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
GBA1 P04062 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13519611 1.00 ALDH1A1 (0.45) ALDH1A1HTR1AKDM4EHRH2HRH1
SCHEMBL12225611 1.00 ALDH1A1 (0.45) ALDH1A1HTR1AKDM4EHRH2HRH1
SCHEMBL7375999 0.89 HTR1A (0.49) ALDH1A1HTR1AKDM4EHRH2HRH1
SCHEMBL13519663 0.88 KCNA3 (0.43) HRH2HRH1HRH3GBA1
SCHEMBL18233564 0.88 KCNA3 (0.43) HRH2HRH1HRH3GBA1
SCHEMBL8085779 0.88 KCNA3 (0.43) HRH2HRH1HRH3GBA1
SCHEMBL18501212 0.84 HTR1A (0.42) ALDH1A1HTR1AKDM4EHRH2HRH1
SCHEMBL6629070 0.82 KDM4E (0.53) ALDH1A1HTR1AKDM4EPOLBTSHR
SCHEMBL16852137 0.82 KDM4E (0.53) ALDH1A1HTR1AKDM4EPOLBTSHR
SCHEMBL18575433 0.82 KDM4E (0.53) ALDH1A1HTR1AKDM4EPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349857-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2013-01-08 US disclosed
US-8349857-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2013-01-08 US disclosed
US-8202879-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-06-19 US disclosed
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-05-17 US disclosed
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-05-17 US disclosed
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity SHIONOGI & CO., LTD. (JP) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity ERBB2, EGFR, ABL1 ALDH1A1 4593/4885HTR1A 489/4885KDM4E 2805/4885
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY ERBB2, EGFR, ABL1 ALDH1A1 4593/4885HTR1A 489/4885KDM4E 2805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.